Literature DB >> 26382622

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.

Maro Ohanian1, Carlos Bueso-Ramos2, Chi Young Ok2, Pei Lin2, Keyur Patel2, Mona Lisa Alattar3, Joseph D Khoury2, Uri Rozovski3, Zeev Estrov3, Yang O Huh2, Jorge Cortes3, Lynne V Abruzzo4.   

Abstract

Little is known about MYC dysregulation in myeloid malignancies, and the authors were unable to find published studies that evaluated MYC protein expression in primary cases of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Herein, we describe the clinical, morphologic, immunophenotypic, cytogenetic, and molecular genetic findings in two MDS/AML cases that contained both MYC rearrangement and the JAK2 V617F mutation. We also demonstrate MYC protein expression by immunohistochemistry in both patients.
Copyright © 2015. Published by Elsevier Inc.

Entities:  

Keywords:  Acute myeloid leukemia; JAK2 V617F mutation; MYC; blastic plasmacytoid dendritic cell neoplasm

Mesh：

Substances：

Year:  2015        PMID： 26382622      PMCID： PMC4835801          DOI： 10.1016/j.cancergen.2015.06.004

Source DB:  PubMed          Journal:  Cancer Genet


  15 in total

1.  c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors.

Authors:  Yinshi Guo; Chao Niu; Peter Breslin; Minghui Tang; Shubin Zhang; Wei Wei; Ameet R Kini; Gladell P Paner; Serhan Alkan; Stephan W Morris; Manuel Diaz; Patrick J Stiff; Jiwang Zhang
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

2.  JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.

Authors:  Koichi Takahashi; Keyur P Patel; Hagop Kantarjian; Rajyalakshmi Luthra; Sherry Pierce; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2013-09-25       Impact factor: 22.113

3.  The JAK2 V617F mutation in de novo acute myelogenous leukemias.

Authors:  J W Lee; Y G Kim; Y H Soung; K J Han; S Y Kim; H S Rhim; W S Min; S W Nam; W S Park; J Y Lee; N J Yoo; S H Lee
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

4.  Acute myelogenous leukaemia with c-myc amplification and double minute chromosomes.

Authors:  K Alitalo; K Saksela; R Winqvist; R Alitalo; J Keski-Oja; M Laiho; M Ilvonen; S Knuutila; A de la Chapelle
Journal:  Lancet       Date:  1985-11-09       Impact factor: 79.321

5.  The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Authors:  Gerlinde Wernig; Jeffrey R Gonneville; Brian J Crowley; Margret S Rodrigues; Mamatha M Reddy; Heidi E Hudon; Christoph Walz; Andreas Reiter; Klaus Podar; Yohan Royer; Stefan N Constantinescu; Michael H Tomasson; James D Griffin; D Gary Gilliland; Martin Sattler
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes.

Authors:  F Solé; F Prieto; L Badia; S Woessner; L Florensa; M R Caballin; M D Coll; C Besses; J Sans-Sabrafen
Journal:  Cancer Genet Cytogenet       Date:  1992-11

7.  Minimally differentiated acute nonlymphocytic leukemia: a distinct entity.

Authors:  E J Lee; A Pollak; R D Leavitt; J R Testa; C A Schiffer
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

8.  Amplification of c-myc and pvt-1 homologous sequences in acute nonlymphatic leukemia.

Authors:  C Asker; C Mareni; D Coviello; S Ingvarsson; M Sessarego; P Origone; G Klein; J Sumeigi
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

9.  Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia.

Authors:  Olaya Villa; Marta Salido; María Encarnación Pérez-Vila; Ana Ferrer; Leonor Arenillas; Carmen Pedro; Blanca Espinet; Cristina Corzo; Sergi Serrano; Soledad Woessner; Lourdes Florensa; Francesc Solé
Journal:  Cancer Genet Cytogenet       Date:  2008-08

10.  Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.

Authors:  U Platzbecker; F Braulke; A Kündgen; K Götze; G Bug; C Schönefeldt; K Shirneshan; C Röllig; M Bornhäuser; R Naumann; J Neesen; A Giagounidis; W-K Hofmann; G Ehninger; U Germing; D Haase; M Wermke
Journal:  Leukemia       Date:  2013-01-28       Impact factor: 11.528
View more
  2 in total

1.  MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Authors:  Maro Ohanian; Uri Rozovski; Rashmi Kanagal-Shamanna; Lynne V Abruzzo; Sanam Loghavi; Tapan Kadia; Andrew Futreal; Kapil Bhalla; Zhuang Zuo; Yang O Huh; Sean M Post; Peter Ruvolo; Guillermo Garcia-Manero; Michael Andreeff; Steven Kornblau; Gautam Borthakur; Peter Hu; L Jeffrey Medeiros; Koichi Takahashi; Marisa J Hornbaker; Jianhua Zhang; Graciela M Nogueras-González; Xuelin Huang; Srdan Verstovsek; Zeev Estrov; Sherry Pierce; Farhad Ravandi; Hagop M Kantarjian; Carlos E Bueso-Ramos; Jorge E Cortes
Journal:  Leuk Lymphoma       Date:  2018-05-09

2.  Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance.

Authors:  Saeid Shahrabi; Ali Ehsanpour; Somayyeh Heidary; Mohammad Shahjahani; Masumeh Maleki Behzad
Journal:  Oncol Rev       Date:  2018-10-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.